ArticleScientific reports2025
Villin like suppresses nasopharyngeal carcinoma proliferation by downregulating MYC.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The initial manifestations of nasopharyngeal carcinoma (NPC) are subtle and imperceptible, leading to unfavorable clinical outcomes and limited therapeutic alternatives among Southeast Asian populations. Deletion of chromosome 3p is a commonly observed genetic alteration in NPC. In our endeavor to elucidate the key genes and pathways driving NPC growth, we have discovered that Villin like (VILL), located at 3p22.2, functions as a novel tumor suppressor gene (TSG) with significantly diminished expression levels in NPC. This finding underscores the tremendous potential of VILL as an unexplored molecule warranting further investigation. Overexpressing VILL effectively inhibits proliferation by inducing G1 phase arrest in NPC cells while its knockdown yields contrasting effects on cell growth regulation. Furthermore, our study demonstrates that VILL targets MYC. Knockdown of VILL and overexpression of MYC significantly enhance proliferation in an immortal nasopharyngeal epithelial cell line NP69. Moreover, we are the first to report that VILL plays a tumor suppressive role in NPC. Consequently, VILL emerges as a novel prognostic biomarker and a potential therapeutic candidate for NPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.